Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

NCT02194595 is registered in ClinicalTrials.gov with Mount Sinai Hospital, Canada as lead sponsor.

NCT NCT02194595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02194595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
Lead sponsor
Mount Sinai Hospital, Canada
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2014
Completion date
February 28, 2022
Enrollment
105 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes